Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OSI and Pfizer study Macugen as AMD maintenance therapy
Neovascular age-related macular degeneration (AMD) is a chronic, progressive disease that may require ongoing management. The 54-week trial will enroll up to 1000 patients at 100 sites across
Neovascular age-related macular degeneration (AMD) is a chronic, progressive disease that may require ongoing management. The 54-week trial will enroll up to 1000 patients at 100 sites across
The pivotal trial will compare thrombin topical (human) to bovine thrombin in achieving intra-operative hemostasis (contol of bleeding) during cardiovascular, neurologic (spine) and general surgery procedures. A total
The new agreement supersedes a previous collaboration agreement entered into by Targeted Genetics, with the International Aids Vaccine Initiative (IAVI) and Columbus Children's Research Institute (CCRI) in 2000,
IR103 is a co-formulation of Remune and a novel synthetic toll-like receptor (TLR-9) agonist adjuvant, Amplivax. The company presented the results at the International Symposium on HIV &
Cycloset is believed to act within the central nervous system principally as a direct dopamine agonist to reset neural pathways controlling peripheral metabolism. Results of published clinical studies
The trial was stopped at the recommendation of an independent data monitoring board based on an interim analysis indicating that it is very unlikely that significant differences in
The company, which has an antibody that targets GM-CSF in preclinical development, said in a presentation at the European Congress of Rheumatology that neutralization of the cytokine may
Initial results from the 2,414 patient phase III trial in advanced chronic heart failure (HF), named ACCLAIM, showed that the study failed to meet its primary endpoint of
The Human Subject Protection and Bioresearch Monitoring (HSP/BIMO) initiative will facilitate the modernization of the regulation of clinical trials and bioresearch monitoring, specifically the protection of human subjects
The first new drug application is for the approval of bazedoxifene, a selective estrogen receptor modulator (SERM) investigated for the prevention of postmenopausal osteoporosis. During menopause women begin